Sotera Health Announces General Counsel Transition and Retirement

Sotera Health ( (SHC) ) has shared an update.

In 2025 Sotera Health posted its 20th consecutive year of revenue growth, with full‑year net revenues rising 5.7% to $1.164 billion and net income increasing to $78 million from $44 million in 2024. Adjusted EBITDA climbed 8.2% to $594 million and Adjusted EPS reached $0.86, backed by strong results at Sterigenics and Nordion, improved margins at Nelson Labs and a leaner balance sheet with net leverage reduced to 3.2x.

Fourth‑quarter 2025 net revenues rose 4.6% to $303 million and net income nearly tripled to $35 million, as pricing and volume tailwinds in Sterigenics offset a cobalt‑60 harvest‑related revenue dip at Nordion and modest growth at Nelson Labs. For the full year, Sterigenics and Nordion delivered high‑single‑digit revenue gains and Nelson Labs expanded segment income despite a small revenue decline, underscoring operational resilience across the portfolio.

For 2026 Sotera Health is projecting net revenues between $1.233 billion and $1.251 billion and Adjusted EBITDA of $632 million to $641 million, signaling mid‑single‑digit growth and Adjusted EPS in the $0.93 to $1.01 range. Planned capital spending of $175 million to $225 million and expectations for strong free cash flow suggest continued investment capacity, though the outlook assumes stable supply of ethylene oxide and cobalt‑60 and manageable inflation and labor costs.

On February 18, 2026, Senior Vice President and General Counsel Alex Dimitrief notified the company he will retire on March 31, 2026, after three years in the role, and then serve for up to 12 months as an advisor on ethylene oxide litigation. Deputy General Counsel and Corporate Secretary Erika Ostrowski will be promoted to Senior Vice President and General Counsel effective April 1, 2026, providing leadership continuity in a key legal position as Sotera Health manages ongoing regulatory and litigation exposures.

The most recent analyst rating on (SHC) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.

Spark’s Take on SHC Stock

According to Spark, TipRanks’ AI Analyst, SHC is a Neutral.

The score is driven primarily by mixed financial fundamentals (strong gross margins but high leverage and weakening free cash flow), supported by a strong uptrend in the stock. Earnings call guidance and execution were constructive (growth, margin expansion, and debt paydown), but the overall rating is capped by a very high P/E valuation and ongoing operational/litigation risks.

To see Spark’s full report on SHC stock, click here.

More about Sotera Health

Sotera Health Company, listed on Nasdaq as SHC, is a global provider of mission‑critical sterilization solutions, laboratory testing and advisory services focused on the healthcare industry. Operating through brands including Sterigenics, Nordion and Nelson Labs, the company serves manufacturers that require reliable sterilization and validation of medical and pharmaceutical products worldwide.

In 2025 Sotera Health posted its 20th consecutive year of revenue growth, with full‑year net revenues rising 5.7% to $1.164 billion and net income jumping to $78 million from $44 million a year earlier. Adjusted EBITDA grew 8.2% to $594 million and Adjusted EPS reached $0.86, supported by strong performances at Sterigenics and Nordion, margin gains at Nelson Labs and an improved net leverage ratio of 3.2x, while sponsors Warburg Pincus and GTCR increased the public float to 80% through secondary share sales.

For the fourth quarter of 2025, net revenues grew 4.6% to $303 million and net income nearly tripled to $35 million, helped by pricing and mix tailwinds in Sterigenics, though Nordion’s quarterly results were pressured by cobalt‑60 harvest timing and Nelson Labs saw only modest growth. Segment data show Sterigenics delivering high‑single‑digit full‑year revenue growth and Nordion and Nelson Labs improving profitability for 2025 overall, underscoring the resilience of the portfolio despite quarterly volatility.

Looking ahead to 2026, Sotera Health guided to net revenues between $1.233 billion and $1.251 billion and Adjusted EBITDA of $632 million to $641 million, implying mid‑single‑digit growth on a constant currency basis, alongside projected Adjusted EPS of $0.93 to $1.01 and capital expenditures of $175 million to $225 million. Management highlighted a strengthened balance sheet and robust free‑cash‑flow outlook as it pursues long‑term growth while monitoring inflation, energy costs and supply continuity for ethylene oxide and cobalt‑60.

On the governance front, the company announced that Senior Vice President and General Counsel Alex Dimitrief notified Sotera Health on February 18, 2026, that he will retire on March 31, 2026, and then serve for up to 12 months as an outside advisor on ethylene oxide litigation matters. Effective April 1, 2026, Deputy General Counsel and Corporate Secretary Erika Ostrowski, who has worked under Dimitrief for the past two years, will be promoted to Senior Vice President and General Counsel, ensuring continuity in legal leadership as the company navigates ongoing regulatory and litigation risks.

Average Trading Volume: 1,940,494

Technical Sentiment Signal: Buy

Current Market Cap: $4.96B

Find detailed analytics on SHC stock on TipRanks’ Stock Analysis page.